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We generated a novel fully human anti-EGFR antibody
showed lower toxicity and higher efficacy in the preclini-
cal, toxicological and pharmacological studies when com-
pared to a commercial drug Cetuximab. In this research,
we aimed to understand the probably mechanism.
Firstly, the mAb prefers binding to higher expression of
EGFR. Its binding avidity on IgG form of the mAb to
EGFR was equivalent to Cetuximab, while the Fab affinity
was significantly lower. As a result, Higher EGFR expres-
sion tissues like tumor obtained the equivalent efficacy as
Erbitux, while normal tissues with lower EGFR expression
consequently showed lower toxicity.
Secondly, the new mAb had higher concentration in
tumor tissue than Erbitux. The accumulation of antibody
in tumor local might induce stronger ADCC effect, and
resulted in higher anti-tumor efficacy than Erbitux in a
Hu-WBC NOD SCID xenograft mice model.
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